
Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results, Reports Cash of $33.1 Million as of Year End
Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results, Reports Cash of $33.1 Million as of Year End Victoria, BC, May 7, 2025--(T-Net)--Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company …